Drugs improvement to combat Trypanosomatidic infections

Drugs improvement to combat Trypanosomatidic infections

If you live in Europe, you may never have heard of 'neglected diseases' from Trypanosomatidic infections. However, in countries like Brazil or Sudan these diseases are endemic.

Neglected diseases are conditions that inflict severe health burdens on the world's poorest people, and they are said to be 'neglected' because they are often overlooked by drug developers. Leishmaniasis, sleeping sickness and represent a huge problem in the lives of people who are affected. Existing drugs to treat them are simply inadequate, presenting problems like inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. Experts say that are urgently needed to address the problem.

NMTRYPI ('New Medicines for Trypanosomatidic Infections') a consortium of nine EU academic institutes and four SMEs, recently launched a programme to answer this call by optimising anti-trypanosomal drugs. The NMTRYPI partners are already well familiar with the anti-trypanosomal drugs in question because they were previously responsible for discovering them. Now, they will build on that work by attempting to progress the lead compounds in these drugs as well as screening fungal natural products and Sudanese medicinal plants to discover new lead compounds for development.

Over the next three years, NMTRYPI's interdisciplinary team will use a common drug discovery platform, established by experts in their respective fields, to develop drug leads which may be used in combination with other drugs. The partners will also work to develop pharmacodynamic biomarkers that enable the proteomic profiling of compound efficacy and early identification of . The platform used by NMTRYPI enables high throughput screening of compound libraries, leads to candidate drugs development, proof of concept testing, and toxicology and safety testing. It will ultimately allow the NMTRYPI team to translate drug leads into drug candidates to enter the international development pipelines.

Neglected diseases like leishmaniasis, sleeping sickness and chagas disease are most prevalent in tropical climates, particularly in areas with unsafe drinking water, poor sanitation, sub-standard housing and little or no access to health care. Unfortunately, can often also lack visibility because they usually do not cause dramatic outbreaks that kill large numbers of people. Rather, they usually exact their toll over a longer period of time, leading to crippling deformities, severe disabilities and/or relatively slow deaths.

More information: For more information, see cordis.europa.eu/projects/rcn/109924_en.html

add to favorites email to friend print save as pdf

Related Stories

Crowdfunding drug discovery

Oct 29, 2013

During his nine years working in the pharmaceutical industry, Michael Pollastri learned to protect his research and data with extreme caution. "In the drug industry, everything is super secret," said Pollastri, now an associate ...

Recommended for you

Can robots help stop the Ebola outbreak?

6 hours ago

The US military has enlisted a new germ-killing weapon in the fight against Ebola—a four-wheeled robot that can disinfect a room in minutes with pulses of ultraviolet light.

New bird flu case in Germany

6 hours ago

A worrying new strain of bird flu has been observed for the first time in a wild bird in northern Germany, the agriculture ministry said Saturday.

Mali announces new Ebola case

Nov 22, 2014

Mali announced Saturday a new case of Ebola in a man who is fighting for his life in an intensive care unit in the capital Bamako.

Plague outbreak kills 40 in Madagascar: WHO

Nov 22, 2014

An outbreak of plague has killed 40 people in Madagascar, the World Health Organization said, warning that the disease could spread rapidly in the country's densely populated capital Antananarivo.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.